Medically Reviewed & Updated: February 14, 2026

Mesothelioma Diagnosis, Stages & Treatment Options

Name: Mesothelioma Diagnosis, Stages & Treatment Options
Creator: Danziger & De Llano, LLP
Published: 2003-01-01

Early and accurate diagnosis is critical for mesothelioma patients. According to WikiMesothelioma.com, up to 50% of mesothelioma cases are initially misdiagnosed. This guide covers every step — from first imaging to the latest immunotherapy and clinical trials.

~50% Initially Misdiagnosed

4 Stages TNM Staging System

41–59% 5-Year HIPEC Survival

$0 Upfront Legal Cost

Recently Diagnosed? Get Help Now

Free case review — find out what compensation may be available.

BBB A+ Accredited Since 2009

Super Lawyers Multiple Years Selected

National Trial Lawyers Top 100 Trial Lawyers

AV Preeminent Martindale-Hubbell Rated

AAJ Member American Association for Justice

Medically reviewed and updated: February 14, 2026 • Sources: American Cancer Society, National Cancer Institute, NCCN Guidelines

How Mesothelioma Is Diagnosed

Diagnosing mesothelioma is a multi-step process that typically begins when a patient with a history of asbestos exposure presents with symptoms such as shortness of breath, chest pain, or abdominal swelling. Because these symptoms overlap with many common conditions, up to 50% of mesothelioma cases are initially misdiagnosed as pneumonia, COPD, or irritable bowel syndrome (WikiMesothelioma.com).

An accurate diagnosis requires a combination of imaging studies, blood biomarker analysis, and — critically — a tissue biopsy. Confirming the specific cell type through biopsy is essential because it directly determines which treatments will be most effective and what survival outcomes can be expected.

Imaging Tests

Imaging is usually the first diagnostic step. The following modalities are used to identify tumors, fluid buildup, and the extent of disease spread:

Chest X-ray — Often the initial study; may reveal pleural effusion (fluid around the lungs) or pleural thickening, prompting further investigation
CT scan (Computed Tomography) — The primary imaging tool for mesothelioma; provides detailed cross-sectional images that show tumor location, size, and involvement of surrounding structures
PET scan (Positron Emission Tomography) — Detects metabolically active cancer cells throughout the body; used to determine whether the cancer has spread to lymph nodes or distant organs
MRI (Magnetic Resonance Imaging) — Provides superior soft tissue contrast; particularly useful for evaluating diaphragm involvement and surgical planning

Blood Biomarkers

Several blood tests can support a mesothelioma diagnosis and help monitor treatment response, though none can confirm the disease on their own:

Soluble Mesothelin-Related Peptides (SMRP) — The MESOMARK assay is FDA-approved for monitoring mesothelioma patients; elevated SMRP levels are found in approximately 84% of patients with epithelioid mesothelioma
Fibulin-3 — A more recently studied biomarker that has shown promise in distinguishing mesothelioma from other pleural diseases in research settings
Osteopontin — Elevated levels may indicate mesothelioma, though this marker is less specific than SMRP

Tissue Biopsy: The Definitive Step

A tissue biopsy is required to confirm a mesothelioma diagnosis. The biopsy determines not only whether cancer is present but also the specific cell type — a distinction that directly affects treatment planning:

Thoracoscopy (VATS) — A minimally invasive surgical procedure in which a small camera is inserted through the chest wall to visualize and biopsy pleural tumors; the most common biopsy method for pleural mesothelioma
Laparoscopy — The equivalent procedure for peritoneal mesothelioma, using small abdominal incisions to access and biopsy peritoneal tissue
CT-guided needle biopsy — A less invasive option using imaging guidance to obtain tissue samples; may yield insufficient tissue for complete cell-type classification in some cases
Open surgical biopsy — Used when less invasive methods do not provide adequate tissue for diagnosis

Why Cell Type Confirmation Matters

Immunohistochemistry (IHC) staining during biopsy analysis identifies the specific mesothelioma cell type — epithelioid, sarcomatoid, or biphasic. This distinction is critical because cell type is one of the strongest predictors of treatment response and survival. Patients should ensure their biopsy is analyzed by a pathologist experienced with mesothelioma to avoid misdiagnosis.

Mesothelioma Staging (TNM System)

Mesothelioma staging describes how far the cancer has progressed. The TNM staging system — used for pleural mesothelioma — evaluates three factors: Tumor extent, lymph Node involvement, and Metastasis (distant spread). Staging is determined through imaging studies and, in some cases, surgical exploration.

Stage at diagnosis is one of the most important factors in determining treatment options and prognosis. Patients diagnosed at Stage 1 or 2 typically have more treatment options — including potentially curative surgery — while Stage 3 and 4 patients may benefit more from systemic therapies and palliative care.

Stage	Tumor Extent	Lymph Nodes	Metastasis	Treatment Options	Median Survival
Stage 1	Localized to one side of the pleural lining	No involvement	None	Surgery (EPP or P/D), chemotherapy, radiation, multimodal	~22.2 months
Stage 2	Spread to adjacent structures (lung, diaphragm)	Possible ipsilateral involvement	None	Surgery, chemotherapy, radiation, multimodal	~20 months
Stage 3	Locally advanced; may involve chest wall, mediastinum	Regional involvement	None	Chemotherapy, immunotherapy, palliative surgery, radiation	~17.9 months
Stage 4	Extensive local spread	Distant involvement possible	Present (distant organs)	Chemotherapy, immunotherapy, palliative care, clinical trials	~14.9 months

Source: SEER database, IASLC staging system. Survival figures are medians from population-level data; individual outcomes vary based on cell type, treatment, and patient health.

Why Staging Matters for Treatment Decisions

Staging determines whether a patient is a candidate for potentially curative surgery or whether systemic treatments are more appropriate. Patients diagnosed at Stage 1 or 2 who undergo multimodal treatment — surgery combined with chemotherapy and/or radiation — have achieved significantly longer survival times than those treated with chemotherapy alone. This is why early detection through prompt medical evaluation after asbestos exposure symptoms is so important.

Note on peritoneal mesothelioma staging: Peritoneal mesothelioma does not use the standard TNM system. Instead, it is typically assessed using the Peritoneal Cancer Index (PCI), which scores tumor distribution across 13 abdominal regions. A lower PCI score generally indicates better candidacy for cytoreductive surgery with HIPEC.

Mesothelioma Cell Types

Mesothelioma is classified into three cell types based on microscopic appearance. Cell type is determined through biopsy and immunohistochemistry and is one of the most significant prognostic factors — directly influencing treatment selection and expected outcomes.

Cell Type	% of Cases	Characteristics	Treatment Response	Prognosis
Epithelioid	50–70%	Uniform, well-defined cells that grow in organized patterns; slowest to spread	Most responsive to surgery and chemotherapy	Best prognosis; median survival 12–24+ months
Sarcomatoid	10–20%	Spindle-shaped, irregular cells that spread rapidly; most aggressive form	Least responsive to conventional treatments	Worst prognosis; median survival 6–12 months
Biphasic	20–30%	Contains both epithelioid and sarcomatoid cells; behavior depends on the dominant cell ratio	Varies; cases with more epithelioid cells respond better	Intermediate prognosis; median survival 10–18 months

Epithelioid Mesothelioma

Epithelioid mesothelioma is the most common cell type, accounting for approximately 50–70% of all diagnoses. These cells grow more slowly and are more cohesive than other types, making them the most responsive to surgery, chemotherapy, and radiation. Patients with epithelioid mesothelioma consistently have the longest survival times across all stages, and they are the best candidates for aggressive multimodal treatment.

Sarcomatoid Mesothelioma

Sarcomatoid mesothelioma is the rarest and most aggressive cell type, representing approximately 10–20% of cases. The elongated, spindle-shaped cells spread quickly and are resistant to most conventional treatments. Because of the poor response to surgery, treatment typically focuses on chemotherapy, immunotherapy, and clinical trials. Notably, emerging research suggests that immunotherapy may be particularly effective for sarcomatoid cases — the CheckMate 743 trial demonstrated that nivolumab plus ipilimumab provided the greatest benefit relative to chemotherapy in patients with non-epithelioid cell types.

Biphasic Mesothelioma

Biphasic mesothelioma contains both epithelioid and sarcomatoid cells and accounts for approximately 20–30% of cases. The prognosis depends heavily on the ratio of cell types: cases with a higher proportion of epithelioid cells behave more like pure epithelioid mesothelioma, while sarcomatoid-dominant biphasic tumors carry a worse prognosis. Accurate biopsy analysis is essential to determine this ratio and guide treatment planning.

Free Assessment

Just Diagnosed with Mesothelioma? Understand Your Options

A mesothelioma diagnosis raises urgent questions about treatment and compensation. Answer three questions to receive personalized guidance.

What stage is the mesothelioma diagnosis?

Question 1 of 3

What type of mesothelioma was diagnosed?

Question 2 of 3

Has treatment begun yet?

Question 3 of 3

You May Qualify

Mesothelioma patients at every stage may be eligible for compensation — including trust funds, settlements, and VA benefits.

Complete the form below for a free, confidential case review — there is no cost and no obligation.

Treatment information updated: February 14, 2026 • Sources: NCCN Guidelines, NCI, peer-reviewed clinical studies

Mesothelioma Treatment Options

Treatment for mesothelioma depends on the stage, cell type, location (pleural vs. peritoneal), and the patient's overall health. The most effective approach for eligible patients is multimodal treatment — combining two or more therapies to target the cancer from multiple angles. Treatment planning should involve a mesothelioma specialist, as the disease requires expertise that general oncologists may not have.

Surgery

Surgery offers the best chance for long-term survival in eligible patients with Stage 1 or 2 mesothelioma and epithelioid or predominantly epithelioid cell type. The two primary surgical procedures for pleural mesothelioma are:

Factor	Extrapleural Pneumonectomy (EPP)	Pleurectomy/Decortication (P/D)
Procedure	Radical surgery to remove gross tumor burden	Lung-sparing surgery to remove pleural lining and visible tumors
What Is Removed	Affected lung, pleura, diaphragm, pericardium	Pleural lining and all visible tumors; lung is preserved
Ideal Candidates	Younger patients with good lung function, early-stage disease	Broader candidate pool; patients who may not tolerate lung removal
Surgical Mortality	Approximately 5–7%	Approximately 1–4%
Recovery	Longer recovery; significant reduction in lung capacity	Shorter recovery; better post-operative quality of life
Median Survival	12–22 months (with multimodal therapy)	16–31 months (with multimodal therapy)

Note: P/D has become increasingly favored by many mesothelioma centers due to lower surgical mortality and comparable long-term survival in multimodal settings. The choice between EPP and P/D should be made by an experienced mesothelioma surgeon based on the individual patient's disease characteristics.

For peritoneal mesothelioma: Cytoreductive surgery (CRS) combined with heated intraperitoneal chemotherapy (HIPEC) is the standard surgical approach. This procedure involves removing all visible tumors from the abdominal cavity and then bathing the area in heated chemotherapy. Multiple studies have reported 5-year survival rates of 41–59% for patients with optimal cytoreduction and epithelioid cell type (Yan et al., Journal of Clinical Oncology; Sugarbaker et al.; WikiMesothelioma.com).

Chemotherapy

Chemotherapy is part of the standard treatment for all stages of mesothelioma, either as a primary treatment or in combination with surgery:

First-line standard: Pemetrexed (Alimta) plus cisplatin — established as the standard regimen since the landmark Vogelzang trial (2003), which demonstrated a median survival of 12.1 months versus 9.3 months with cisplatin alone
Alternative first-line: Pemetrexed plus carboplatin — used for patients who cannot tolerate cisplatin; similar efficacy with a more manageable side-effect profile
Second-line options: Gemcitabine, vinorelbine, or retreatment with pemetrexed-based regimens for patients who initially responded
Adjuvant chemotherapy: Administered after surgery to eliminate residual microscopic disease
Neoadjuvant chemotherapy: Administered before surgery to shrink tumors and improve surgical outcomes

Immunotherapy

Immunotherapy represents one of the most significant treatment advances for mesothelioma in recent years. These drugs work by enabling the patient's own immune system to recognize and attack cancer cells:

Nivolumab + Ipilimumab (Opdivo + Yervoy) — FDA-approved in October 2020 as a first-line treatment for unresectable pleural mesothelioma based on the CheckMate 743 trial. This combination demonstrated a median overall survival of 18.1 months versus 14.1 months with chemotherapy. The benefit was most pronounced in patients with non-epithelioid cell types.
Pembrolizumab (Keytruda) — A PD-1 checkpoint inhibitor used in clinical trials and off-label settings for mesothelioma patients who have progressed on first-line chemotherapy
Checkpoint inhibitor combinations — Ongoing clinical trials are evaluating immunotherapy combined with chemotherapy, surgery, and radiation to determine optimal sequencing

Established Science vs. Emerging Research

The nivolumab-ipilimumab combination is the only FDA-approved immunotherapy for mesothelioma as of early 2026. Other immunotherapy agents are being studied in clinical trials but are not yet approved specifically for this indication. Patients should discuss with their oncologist whether immunotherapy, chemotherapy, or a combination is most appropriate for their specific diagnosis.

Radiation Therapy

Radiation therapy uses high-energy beams to destroy cancer cells or slow their growth. In mesothelioma, radiation serves different purposes depending on the treatment context:

Intensity-Modulated Radiation Therapy (IMRT) — Precisely targets tumors while minimizing damage to surrounding healthy tissue; used as part of multimodal treatment after surgery
Proton therapy — Delivers radiation with even greater precision than IMRT; available at specialized centers and under active study for mesothelioma
Curative-intent radiation — Used in combination with surgery and chemotherapy as part of a multimodal treatment plan aiming for maximum disease control
Palliative radiation — Targets specific areas to relieve pain, reduce tumor burden, and improve quality of life when curative treatment is not feasible
Prophylactic radiation — Applied to surgical incision sites to prevent tumor seeding after biopsy or surgical procedures

Multimodal Treatment: The Gold Standard

The most favorable survival outcomes in mesothelioma are consistently achieved with multimodal treatment — combining surgery, chemotherapy, and/or radiation therapy. The specific combination depends on the patient's stage, cell type, and overall health:

Surgery + Chemo + Radiation Standard Multimodal Approach

CRS + HIPEC Peritoneal Mesothelioma Standard

Immuno + Chemo Emerging Combination Under Study

Research by Sugarbaker and colleagues has shown that patients receiving trimodal therapy (surgery, chemotherapy, and radiation) can achieve median survival times significantly exceeding those who receive single-modality treatment. For peritoneal mesothelioma patients, the CRS/HIPEC approach has transformed a disease with a historically poor prognosis into one with legitimate long-term survivorship for many patients.

Emerging Treatments & Clinical Trials

While established treatments continue to improve outcomes, the next generation of mesothelioma therapies is being evaluated in clinical trials. These emerging approaches represent active areas of research — not yet standard of care — but several have shown promising early results.

Tumor Treating Fields (TTFields) — A non-invasive device (NovoTTF-100L/Optune Lua) that delivers low-intensity, alternating electric fields to disrupt cancer cell division. The STELLAR trial showed a median overall survival of 18.2 months when TTFields were combined with pemetrexed-platinum chemotherapy for unresectable pleural mesothelioma. TTFields received FDA humanitarian device exemption for mesothelioma.
Gene therapy — Approaches include introducing tumor-suppressor genes (such as BAP1) into mesothelioma cells and using modified viruses to selectively kill cancer cells. Several Phase I/II trials are ongoing.
Targeted molecular therapy — Drugs designed to target specific genetic mutations or molecular pathways in mesothelioma cells, including anti-angiogenic agents (bevacizumab) and drugs targeting the Hippo signaling pathway
CAR T-cell therapy — Engineered immune cells targeting mesothelin on the surface of mesothelioma cells; early-phase clinical trials have shown encouraging safety and preliminary efficacy signals
Photodynamic therapy (PDT) — Light-activated drugs that destroy cancer cells when exposed to specific wavelengths during surgery; studied as an intraoperative adjunct
Novel immunotherapy combinations — Trials evaluating immunotherapy combined with chemotherapy, radiation, or other immune-modulating agents to improve response rates beyond what current regimens achieve
Pressurized Intraperitoneal Aerosol Chemotherapy (PIPAC) — An emerging minimally invasive technique that delivers aerosolized chemotherapy directly into the abdominal cavity under pressure, allowing better tissue penetration with lower systemic toxicity. Early studies show promise for peritoneal mesothelioma patients who are not candidates for traditional CRS/HIPEC (WikiMesothelioma.com).

Finding Mesothelioma Clinical Trials

Patients can search for active mesothelioma clinical trials through ClinicalTrials.gov (the NIH registry), the National Cancer Institute (cancer.gov), and major mesothelioma treatment centers. A mesothelioma specialist can evaluate whether a specific trial is appropriate based on your diagnosis, stage, cell type, and treatment history. Clinical trials provide access to cutting-edge therapies and are an important option for patients at all stages.

📖 Treatment Options
& Clinical Trials Free Guide

Free — No Obligation

Mesothelioma Treatment Guide: Every Option Explained in Plain Language

From surgery options (EPP vs. P/D) to the latest FDA-approved immunotherapy combinations and emerging clinical trials, this guide helps patients and families understand every treatment pathway — and how to afford the best care through compensation.

Surgery options compared: EPP, P/D, and cytoreductive surgery
Chemotherapy protocols: cisplatin + pemetrexed and beyond
FDA-approved immunotherapy: nivolumab + ipilimumab (CheckMate 743)
HIPEC for peritoneal mesothelioma: 41–59% 5-year survival
How to find and enroll in clinical trials
Compensation options to help cover treatment costs

Survival statistics updated: February 14, 2026 • Sources: SEER database, NCI, NCCN, peer-reviewed studies

Mesothelioma Prognosis by Stage & Type

Prognosis for mesothelioma depends on the interplay of several factors, with stage, cell type, and treatment approach being the most significant. The statistics below represent population-level data from published studies and cancer registries. Individual outcomes may differ based on patient health, treatment center expertise, and response to therapy.

Stage / Type	Median Survival	1-Year Survival Rate	5-Year Survival Rate
Stage 1 (Pleural)	~22.2 months	~73%	~16–20%
Stage 2 (Pleural)	~20 months	~65%	~10–15%
Stage 3 (Pleural)	~17.9 months	~50%	~5–10%
Stage 4 (Pleural)	~14.9 months	~35%	~1–5%
Peritoneal (with HIPEC)	~53 months	~85%	~50%+
Epithelioid (all stages)	~12–24 months	~60–70%	~10–15%
Sarcomatoid (all stages)	~6–12 months	~25–40%	~1–5%
Biphasic (all stages)	~10–18 months	~40–55%	~5–10%

Sources: SEER Cancer Statistics Review, NCI; Yan et al., Journal of Clinical Oncology; Sugarbaker et al. Survival data represent ranges from multiple published studies. Individual results vary.

Factors That Improve Prognosis

While mesothelioma remains a serious diagnosis, several factors are associated with significantly improved survival outcomes:

Early-stage diagnosis (Stage 1–2) — Patients with localized disease have access to potentially curative surgical options
Epithelioid cell type — The most treatment-responsive cell type with the longest survival across all treatment modalities
Multimodal treatment — Combining surgery with chemotherapy and/or radiation consistently produces better outcomes than any single treatment
Treatment at a specialized center — Surgeons and oncologists with mesothelioma expertise achieve better outcomes than general practitioners treating the disease occasionally
Good overall health (performance status) — Patients who are physically active and have fewer comorbidities tolerate aggressive treatment better
Younger age at diagnosis — Patients under 65 typically tolerate surgery and multimodal therapy more effectively
Female sex — Studies consistently show slightly better survival for female mesothelioma patients, though the reasons remain under investigation

For a broader overview of mesothelioma types and general prognosis information, visit our mesothelioma overview page.

Co-Founder & Lead Attorney

Paul Danziger

Texas Bar #00788880 • Admitted 1993 • Northwestern University School of Law

Paul Danziger has spent over 30 years representing mesothelioma patients and their families across the United States. He co-founded Danziger & De Llano, LLP with the mission of providing the personal attention and aggressive advocacy that asbestos victims deserve.

Before law school, Paul earned his B.B.A. and a Master's degree in Tax Accounting from the University of Texas and worked as a CPA and tax consultant in New York. His unique financial and legal background gives him a distinctive ability to evaluate complex mesothelioma cases and maximize compensation for his clients.

Paul has been named a Texas Super Lawyer multiple times (2006–2009, 2014–2016, 2024) and was recognized as one of the Top 100 Trial Lawyers by the National Trial Lawyers. He is also the executive producer and co-writer of the film Puncture (starring Chris Evans), based on a real product liability case he was involved in.

30+ Years in Practice

Super Lawyers Multiple Years

Top 100 National Trial Lawyers

Speak with Paul About Your Case

Free consultation. No obligation. No fees unless we win.

Co-Founder & Senior Trial Attorney

Rodrigo “Rod” de Llano

Texas Bar #00786666 • Admitted 1993 • Northwestern University School of Law • Princeton University (Economics)

Rod de Llano brings a unique combination of Ivy League education, international business experience, and decades of litigation expertise to every mesothelioma case. After graduating from Princeton with a degree in Economics and managing an international import/export business, Rod earned his law degree from Northwestern University School of Law.

Rod began his legal career in the general litigation section of a large international law firm, handling commercial liability and insurance coverage disputes. His breadth of experience — spanning product liability, whistleblower cases, antitrust matters, class actions, and intellectual property — gives him a strategic advantage in complex mesothelioma litigation where multiple parties and jurisdictions are involved.

Rod holds an AV Preeminent rating from Martindale-Hubbell (the highest distinction for legal ability and ethical standards) and has been named a Thomson Reuters Texas Super Lawyer from 2013 through 2019.

30+ Years in Practice

AV Preeminent Martindale-Hubbell

Princeton University

Speak with Rod About Your Case

Free consultation. No obligation. No fees unless we win.

Get Help With Treatment Costs & Compensation

Mesothelioma treatment is expensive, but you may be entitled to significant compensation to cover medical costs, lost wages, and your family's future security. Our experienced attorneys have helped thousands of mesothelioma families recover funds from asbestos trust funds and lawsuits — while you focus on treatment.

Free & Confidential No upfront costs, no hidden fees. You pay nothing unless we recover compensation.

Nationwide Representation Licensed to handle mesothelioma cases in all 50 states from our Houston office.

Over 25 Years of Experience Our attorneys have recovered over $1 billion for mesothelioma patients and families.

Fast Results Trust fund claims can resolve in as few as 90 days. We move quickly for our clients.

Or call us 24/7: 1-866-222-9990

FAQ answers reviewed by medical-legal team: February 14, 2026

Frequently Asked Questions About Mesothelioma Diagnosis & Treatment

How is mesothelioma diagnosed?

Mesothelioma is diagnosed through a multi-step process that includes imaging tests (CT scans, X-rays, PET scans), blood biomarker tests (mesothelin, fibulin-3), and a tissue biopsy. A biopsy is required to confirm the diagnosis and identify the cell type — epithelioid, sarcomatoid, or biphasic — which directly determines treatment options and prognosis.

What are the stages of mesothelioma?

Mesothelioma is staged using the TNM system from Stage 1 through Stage 4. Stage 1 means the cancer is localized to the mesothelial lining with no lymph node involvement. Stage 2 involves limited spread to nearby structures. Stage 3 means regional lymph node involvement. Stage 4 indicates distant metastasis. Earlier stages have significantly better treatment options and survival rates.

What is the best treatment for mesothelioma?

The most effective treatment is multimodal therapy — a combination of surgery, chemotherapy, and radiation. For eligible patients, surgery such as pleurectomy/decortication (P/D) combined with chemotherapy (pemetrexed plus cisplatin) and radiation produces the longest survival times. For peritoneal mesothelioma, cytoreductive surgery with HIPEC has achieved 5-year survival rates exceeding 50%.

What is the difference between EPP and P/D surgery?

Extrapleural pneumonectomy (EPP) removes the entire affected lung, pleural lining, diaphragm, and pericardium. Pleurectomy/decortication (P/D) removes the pleural lining and visible tumors while preserving the lung. P/D has become increasingly favored due to lower surgical mortality (~1–4% vs. ~5–7%), shorter recovery, and comparable long-term survival in many cases.

Does immunotherapy work for mesothelioma?

Yes. The FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) in October 2020 as a first-line treatment for unresectable pleural mesothelioma. This immunotherapy combination showed a median overall survival of 18.1 months compared to 14.1 months with chemotherapy alone. The benefit was most pronounced in patients with non-epithelioid cell types.

What is the survival rate for mesothelioma by stage?

Survival varies by stage. Stage 1 median survival is approximately 22.2 months with some 5-year survival rates of 16–20%. Stage 2 median is approximately 20 months. Stage 3 median is approximately 17.9 months. Stage 4 median drops to approximately 14.9 months. Early detection and multimodal treatment can substantially improve these figures.

What are mesothelioma cell types and why do they matter?

The three cell types are epithelioid (50–70% of cases, best prognosis), sarcomatoid (10–20%, worst prognosis), and biphasic (20–30%, mixed prognosis). Cell type is determined through biopsy and directly affects which treatments are most likely to be effective and the expected survival time.

Are there clinical trials for mesothelioma?

Yes. Active trials are studying gene therapy, tumor treating fields (TTFields), targeted molecular therapies, CAR T-cell therapy, and novel immunotherapy combinations. Patients can search for trials at ClinicalTrials.gov or through the National Cancer Institute. A mesothelioma specialist can help determine which trials may be appropriate for your diagnosis.

What blood tests are used to detect mesothelioma?

Blood biomarker tests include soluble mesothelin-related peptides (SMRP), fibulin-3, and osteopontin. The MESOMARK assay for SMRP is FDA-approved for monitoring mesothelioma. While these tests can support a diagnosis and monitor treatment, they cannot confirm mesothelioma alone — a tissue biopsy is required for definitive diagnosis.

Can mesothelioma patients get compensation for treatment costs?

Yes. Patients may recover compensation for treatment costs, lost income, pain and suffering, and other damages through asbestos trust funds (over $30 billion available), personal injury lawsuits, and VA benefits for veterans. An experienced mesothelioma attorney can identify all sources of compensation while you focus on treatment.

This page was last reviewed and updated on February 14, 2026 by the medical-legal team at Danziger & De Llano, LLP.

Diagnosed With Mesothelioma? We Can Help.

Understanding your diagnosis and treatment options is critical — and so is knowing your legal rights. Our team has spent over 25 years helping mesothelioma patients and families secure the compensation they need for treatment, financial stability, and peace of mind.

Call 1-866-222-9990 Request a Free Case Review

Free consultation • No obligation • Available 24/7 • No fees unless we win

BBB A+ Accredited 4.8★ Google Rating $1B+ Recovered 25+ Years Experience